Top Industry Leaders in the Appendiceal Cancer Treatment Market
Latest Appendiceal Cancer Treatment Companies Updates:
Merck KGaA announces promising early data from a Phase 2 clinical trial of KEYTRUDA® (pembrolizumab) for treating advanced unresectable appendix cancer, showing positive response rates and highlighting the potential of immunotherapy in this setting.
Genentech receives FDA Breakthrough Therapy designation for its investigational antibody-drug conjugate Polatuzumab vedotin, designed for treating patients with locally advanced or metastatic appendiceal cancer who have progressed on prior chemotherapy.
Boston Scientific introduces its portfolio of advanced surgical instruments specifically designed for minimally invasive laparoscopic appendiceal cancer surgery, offering surgeons precision and improved control.
The National Cancer Institute (NCI) partners with academic institutions and pharmaceutical companies to fund research on improving appendiceal cancer diagnosis, treatment, and clinical trials.
List of Appendiceal Cancer Treatment Key companies in the market:
- AbbVie, Inc.
- Pfizer Inc.
- Eli Lilly & Company
- Bristol-Myers Squibb Company
- F. Hoffman-La Roche Ltd.
- Novartis AG
- General Electric Company
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Bayer AG
- Amgen Inc.